Investigating and comparing the effect of ketorolac 30 mg intravenous and haloperidol 5 mg intravenous in reducing the intensity of primary headache in patients with the chief complaint of headache at the emergency department of Sina Hospital.

Determining and comparing the effect of Ketorolac 30 mg IV and haloperidol 5 mg IV in reducing the severity of headache in patients with the chief complaint of headache at the emergency department of Sina Hospital.

1 ml ampoules of 5 mg of haloperidol and 30 mg of ketorolac will be used. The pharmacist covers the ampoules and puts them in the envelope. Then he picks the envelopes in the order of the random sequence and delivers them to the researcher. Unawareness of patients, health care providers, and outcome reviewers was ensured as to which intervention group they were placed in.

Blinding of the patient and the researcher is done in the emergency room of Sinai Hospital

People aged 18 to 55 years who went to the emergency room with the main complaint of headache. Exclusion: Abnormal blood pressure (> 100/200 mmHg) Sudden or rapid onset Fever Acute trauma History of brain mass History of stroke History of abnormal intracranial anatomy QTc > 450 ms on the heart monitor strip Altered mental status Allergy to haloperidol Allergy to ketorolac Airway diseases such as asthma Active peptic ulcer Advanced renal failure Recent major surgery new abnormal findings on neurological examination clinical doubt of the doctor that requires a CT scan of the brain or Lumbar Puncture pregnancy drugs that prolong the QT interval hepatic failure Epilepsy or history of seizures hyperthyroidism parkinsonism Chronic psychiatric disease Concomitant use or within 2 weeks of discontinuing an MAOI Active gastritis or peptic ulcer disease History of upper gastrointestinal bleeding Previous participation in the same study Dissatisfaction

Two groups with headaches were referred to the emergency room, one group was randomly intravenous ketorolac, and the other group with IV haloperidol.

pain reduction

Grouping of patients based on the balanced block randomization method will be done in groups A and B. First, blocks of 4 including 6 modes are defined and a number from 1 to 6 is considered by the executive supervisor of the plan for each of these blocks and the number of blocks is determined based on the number of the determined sample volume and the number of the desired blocks is cast. and the last patient will be determined in order and the randomized list will be provided to the project manager in order. At each visit, the patients will be entered into two groups A and B based on the previously determined order. This process continues until the examination of the last patient based on the specified sample size.

The pharmacist covers the ampoules with labels and puts them in the envelope. (He knows the type of ampoule in each envelope) Then he picks the envelopes according to the random sequence given to him and delivers them to the researcher. In the following, envelopes will be used for the participants in order (for example, the first patient envelope number 1 and the fifth patient envelope number 5). In this way, it is ensured that the patients and health care providers who prescribe the drugs and the outcome examiners (pain score and possible complications) are not aware of which intervention group they are placed in.

part of data ; main consequences , adverse consequences

6 months after publish

Physician

request permission

to researcher

email to researcher